Managing Infections Caused by Extended-Spectrum-β-Lactamase Producing Enterobacterales and Carbapenem-Resistant Enterobacterales: Pfizer Home-Study
At the completion of this activity, the participant will be able to:
- Recognize the common mechanisms of antimicrobial resistance in Enterobacterales
- Recognize susceptibility reports for β-lactamase- producing Enterobacterales and select appropriate antimicrobial therapy
- Define carbapenem-sparing options for the treatment of extended spectrum β-lactamase (ESBL) Enterobacterales
- State the role of ceftazidime-avibactam, meropenem-vaborbactam, and other novel agents for the treatment of carbapenem-resistant Enterobacterales (CRE)
Dr. Jason Hedvat, PharmD, BCIDP received his Doctor of Pharmacy at the Ernest Mario School of Pharmacy, Rutgers University. He then completed his PGY1 Pharmacy Residency at Hackensack University Medical Center and PGY2 Infectious Diseases Pharmacy Residency at NewYork-Presbyterian Hospital. He is currently employed as the infectious diseases clinical pharmacy manager at Mount Sinai Beth Israel and New York Eye and Ear Infirmary of Mount Sinai. His clinical interests include gram-negative resistance, antimicrobial stewardship in immunocompromised patients, and optimizing pharmacokinetic & pharmacodynamic of antimicrobials.
There is no conflict of interest with the presenter and this activity.
This is a knowledge based activity
- 1.00 ACPEThe Arnold & Marie Schwartz College of Pharmacy and Health Sciences is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.